Literature DB >> 35247061

Value of contrast-enhanced ultrasound for diagnosis and follow-up of renal artery stenosis in patients with chronic kidney disease.

Tianhui Li1, Yonghui Mao2, Ban Zhao1, Haitao Wang1, Junhong Ren3, Na Ma3, Siyu Wang3.   

Abstract

OBJECTIVE: To evaluate whether contrast-enhanced ultrasound (CEUS) is an accurate, non-nephrotoxic diagnostic method and follow-up tool for use in patients with chronic kidney disease (CKD) and renal artery stenosis (RAS).
METHODS: In this prospective and monocentric study, we compared the sensitivity and specificity of CEUS for the diagnosis of RAS in CKD patients, using digital subtraction angiography (DSA) or computed tomographic angiography (CTA) as the gold standard methods. Further, the value of CEUS for distinguishing restenosis from other diseases was assessed. The ultrasound physicians conducted the examinations and served as the CEUS report readers who were blinded to the DSA or CTA results.
RESULTS: Patients with RAS (n = 60) were enrolled. Average patient age was 64.4 ± 18.0 years and median estimated glomerular filtration rate was 66.1 mL/min/1.73 m2. CEUS was used to image 94 stenotic renal arteries and DSA- or CTA-verified stenosis was present in 96 renal arteries. The kappa value for CEUS was 0.776 (P < 0.001), with an accuracy of 92.5%, a sensitivity of 94.7%, and a specificity of 84.0%. The accuracy of CEUS was the same for the diagnosis of the CKD3b-5 group as for the CKD1-3a group (100% vs. 87.5%, P = 0.148). There was no difference in CEUS accuracy for the diagnosis of Takayasu RAS compared with atherosclerotic RAS (95.8% vs. 91.7%, P = 0.795). Twenty-nine CEUS examinations were performed to follow in-stent restenosis or progression of RAS, with a median follow-up time of 5.0 months (range 1.0-20.0). Two cases of in-stent restenosis in patients suffering from deteriorating kidney function and recurrent hypertension were examined by CEUS.
CONCLUSION: CEUS examination is a credible alternative for diagnosing moderate and severe RAS in patients with CKD, and is a reliable tool for follow-up surveillance after renal artery revascularization treatment. It shouldn't be thought as a color-coded duplex ultrasonography rescue in these patients.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Chronic kidney disease; Contrast-enhanced ultrasound; Renal artery stenosis

Mesh:

Substances:

Year:  2022        PMID: 35247061     DOI: 10.1007/s00261-022-03457-w

Source DB:  PubMed          Journal:  Abdom Radiol (NY)


  24 in total

Review 1.  Renal Artery Stenosis and Congestive Heart Failure: What Do We Really Know?

Authors:  Rajesh Gupta; Mubbasher Syed; Nikita Ashcherkin; Katherine Chen; Palavi P Vaidya; Christopher J Cooper
Journal:  Curr Cardiol Rep       Date:  2019-06-24       Impact factor: 2.931

2.  Imaging modalities for renal artery stenosis in suspected renovascular hypertension: prospective intraindividual comparison of color Doppler US, CT angiography, GD-enhanced MR angiography, and digital substraction angiography.

Authors:  C Rountas; M Vlychou; K Vassiou; V Liakopoulos; E Kapsalaki; G Koukoulis; I V Fezoulidis; I Stefanidis
Journal:  Ren Fail       Date:  2007       Impact factor: 2.606

3.  Contrast-enhanced ultrasound versus conventional ultrasound and MS-CT in the diagnosis of abdominal aortic dissection.

Authors:  D-A Clevert; A Horng; D-A Clevert; E M Jung; W H Sommer; M Reiser
Journal:  Clin Hemorheol Microcirc       Date:  2009       Impact factor: 2.375

4.  Renal artery evaluation: comparison of spiral CT angiography to intra-arterial DSA.

Authors:  T S Kim; J W Chung; J H Park; S H Kim; K M Yeon; M C Han
Journal:  J Vasc Interv Radiol       Date:  1998 Jul-Aug       Impact factor: 3.464

5.  The EFSUMB Guidelines and Recommendations on the Clinical Practice of Contrast Enhanced Ultrasound (CEUS): update 2011 on non-hepatic applications.

Authors:  F Piscaglia; C Nolsøe; C F Dietrich; D O Cosgrove; O H Gilja; M Bachmann Nielsen; T Albrecht; L Barozzi; M Bertolotto; O Catalano; M Claudon; D A Clevert; J M Correas; M D'Onofrio; F M Drudi; J Eyding; M Giovannini; M Hocke; A Ignee; E M Jung; A S Klauser; N Lassau; E Leen; G Mathis; A Saftoiu; G Seidel; P S Sidhu; G ter Haar; D Timmerman; H P Weskott
Journal:  Ultraschall Med       Date:  2011-08-26       Impact factor: 6.548

6.  Contrast-Induced Nephropathy in Ischemic Stroke Patients Undergoing Computed Tomography Angiography: CINISter Study.

Authors:  Anthony Shaun Rowe; Brandon Hawkins; Leslie A Hamilton; Andrew Ferrell; Jennifer Henry; Brian F Wiseman; Steven A Skovran; Mitra S Mosadegh; Marion E Hare; Mehmet Kocak; Elizabeth Tolley
Journal:  J Stroke Cerebrovasc Dis       Date:  2018-12-07       Impact factor: 2.136

Review 7.  Ischemic nephropathy: more than a simple renal artery narrowing.

Authors:  Mohammad Reza Khatami
Journal:  Iran J Kidney Dis       Date:  2013-03       Impact factor: 0.892

8.  Use of Intravenous Iodinated Contrast Media in Patients with Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation.

Authors:  Matthew S Davenport; Mark A Perazella; Jerry Yee; Jonathan R Dillman; Derek Fine; Robert J McDonald; Roger A Rodby; Carolyn L Wang; Jeffrey C Weinreb
Journal:  Radiology       Date:  2020-01-21       Impact factor: 11.105

9.  An uninvestigated risk factor for contrast-induced nephropathy in chronic kidney disease: proteinuria.

Authors:  Serhan Piskinpasa; Bulent Altun; Hadim Akoglu; Tolga Yildirim; Kemal Agbaht; Rahmi Yilmaz; Bora Peynircioglu; Barbaros Cil; Kudret Aytemir; Cetin Turgan
Journal:  Ren Fail       Date:  2012-11-23       Impact factor: 2.606

10.  Renal insufficiency as a predictor of adverse events and mortality after renal artery stent placement.

Authors:  David J Kennedy; William R Colyer; Pamela S Brewster; Mary Ankenbrandt; Mark W Burket; Attila S Nemeth; Sadik A Khuder; William J Thomas; Joseph I Shapiro; Christopher J Cooper
Journal:  Am J Kidney Dis       Date:  2003-11       Impact factor: 8.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.